Fri, Dec 26, 2014, 9:03 PM EST - U.S. Markets closed


% | $
Quotes you view appear here for quick access.

OCZ Technology Group Inc Message Board

bullseyecatnip 17 posts  |  Last Activity: Dec 23, 2014 10:36 AM Member since: May 25, 2011
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    Massive Inside Sales Since 2/2013, $43

    by bullseyecatnip Dec 23, 2014 10:25 AM
    bullseyecatnip bullseyecatnip Dec 23, 2014 10:36 AM Flag

    Thumbs down all you want. GILD is a good drug company but these are FACTS.

  • Check the charts yourself.
    Unbelievable how well executives and those in early have done. Good for them.

  • Reply to

    Shorts are in control till positive sales data

    by robertellin Dec 22, 2014 10:27 AM
    bullseyecatnip bullseyecatnip Dec 22, 2014 11:53 AM Flag

    KERX is in control. It's time to execute long into the future.
    Best wishes to longs and Merry Christmas and Happy New Year!

  • Reply to

    Nobody Knows

    by usedbearing Dec 16, 2014 10:45 PM
    bullseyecatnip bullseyecatnip Dec 17, 2014 5:37 AM Flag

    Not worth speculating about what might happen next. And I've been guilty of this. What we know is that official company press releases and conference calls will provide updates on significant news going forward. Take comfort knowing we have an approved drug with patent protection and fair pricing that can save lies and improve quality of life in a sadly growing market, which means plenty of potential to be successful enough to make this good investment continue.

  • Reply to


    by dasurrealcafe Dec 13, 2014 4:05 AM
    bullseyecatnip bullseyecatnip Dec 13, 2014 6:34 AM Flag

    I'm believe a few large Pharma have already vetted this company. Perhaps a ballon was floated that wasn't close to being high enough. Perhaps the suitor if any will wait a few Qs after launch to see how they do and will see if a price war developed where KERK largest competitor lowers the price of their competitive product by 10-20%, While some launches do poorly and others do very well... I'm hopeful because their sales team is already hired, trained and on the streets targeting a market that can be penetrated with a small focused team. Although chances are slim now, could still be BO by YE. More likely they are taken out Q3 or so C15. And if not they are likely doing very well standalone! We shall see. In any event, although KERX is my largest small biopharma holding I will watch the price as it gets more tempting to add with each drop. Good news we know is that patent protection is outstanding and vast majority of risk is off the table. And sadly for families, the need will be growing for decades to come, All that's left now is execution and market acceptance.

  • Put the narcissist "chad" virus feeds on attention. Let's ALL put on ignore. Do NOT respond in any way and it will eventually go elsewhere. Makes for a better board.

  • bullseyecatnip bullseyecatnip Dec 8, 2014 1:16 PM Flag

    People are acting as if we will never see $80-100-120 oil again. We will. We WLL.

  • bullseyecatnip by bullseyecatnip Dec 6, 2014 6:19 AM Flag

    Many thanks to all longs for the wealth information you have shared so unselfishly and without hidden-agendas over the years. No doubt your research and wisdom helped many of use stay in the game much longer that we might have otherwise. Wishing a very peaceful and happy holiday season to you and yours, as well as, long into the future.

  • Reply to

    Kerx/Roche talking?

    by burghboy88 Nov 23, 2014 5:41 PM
    bullseyecatnip bullseyecatnip Nov 25, 2014 6:17 AM Flag

    Although a broken clock is right once in a while.... Sierra is a self-serving dirty rag that has no history of any value. I'm long KERX and believe a BO is possible and very likely... could be this year or before this time 2015 and if not I'm confident KERX will do very well standalone. Sierra is the last place that you should reply on for quality information.

  • bullseyecatnip by bullseyecatnip Nov 24, 2014 7:24 AM Flag

    Thank you to everyone who has helped educate me about AVNR over the years, especially during the most difficult times. Although stumbling and slow getting out of the gate, AVNR's PPS has done very well since I purchased and added. I continue to remain long, holding a majority of my original purchases and additions.

    I have growing confidence that new indications will show great promise and are what's needed to make this company successful as standalone or as an acquisition. I'll check in on official AVNR news and update my alerts, but so many distractions concerning this trade/congo person take away from this board being all that it could be. (I realize, its like this on many boards.) While I agree with you good longs who counter his recent months of verbal pollution... I can't help but be reminded of what a much more enjoyable board this was in his absence - if only for a while.

    Best wishes for a peaceful, happy, and healthy holidays and 2015 to all of you and your families!

  • bullseyecatnip bullseyecatnip Nov 23, 2014 7:51 AM Flag

    I owned PCYC that I discover in 5s and was convinced in a weak moment to sell 2500 shares at 11s. The same financial advisor told me to sell MU at 10-11s and intel at 17, Advised me not to buy Netflix at 70 and add to Apple at 280... I could go on and on. I later fired this person for so much bad advice it can still upset me a little today. .. bad advice and fees. This person and firm is gone and I've been on my own.

    Although I did not purchase Netflix (on that advice)....
    Years later I added to to Apple.
    Added to intel at 19, 22 and 25.
    Added to MU at 12,14 and 18. Never selling a share until I trimmed a little recently.
    What will KERX do - I don't know. I sold a very small percentage of my shares once and bought back twice. Surprise news could cause me to bail on KERX... I cannot predict the future, but for now I and long KERX. I certainly feel better owning now than years ago. Much of that old risk has been vetted. I truly believe there is chance the company is sold before they launch and very likely they are sold before YE15. And if not, they will be very successful... good for patients, their families and KERX shareholders for many years to come.

  • Reply to

    23rd Alzheimer Europe Conference in Malta

    by theefalcon Nov 21, 2014 4:03 AM
    bullseyecatnip bullseyecatnip Nov 21, 2014 7:31 AM Flag

    Greatly appreciated. Any time I get a little impatient or concerned you come up with some gems of hope.

  • Reply to

    Here I Go Again....

    by rainmulti Oct 31, 2014 7:55 PM
    bullseyecatnip bullseyecatnip Nov 1, 2014 3:24 AM Flag

    This company could be acquired any day! Maybe this year maybe next year and if they have a successful launch and are not acquired by this time 2015, they will be rocking as a independent success story!

  • Reply to

    Beats and Good News

    by bullseyecatnip Oct 28, 2014 8:05 AM
    bullseyecatnip bullseyecatnip Oct 28, 2014 8:14 AM Flag

    I like the PICO news the best and that all sales territories are performing better again and acquisition jitters made channels slow down as their was uncertainty about some of their futures... this cloud appears to have lifted quickly. Kudos to their sales management and teams.

  • bullseyecatnip by bullseyecatnip Oct 28, 2014 8:05 AM Flag

    hird-Quarter 2014 Highlights

    Revenue up 18% year-over-year to $71.5 million
    Non-GAAP net income of $5.5 million, or $0.25 per diluted share, excluding amortization expenses, acquisition costs and unrealized foreign exchange loss
    GAAP net income of $3.1 million, or $0.14 per diluted share, including amortization expenses, acquisition costs and unrealized foreign exchange loss
    $113 million in cash and investments at September 30, 2014
    Repurchased $6.6 million of common stock under share repurchase program
    Acquired assets of RF medical device manufacturer Ellman International, Inc.
    "Cynosure delivered record third-quarter revenue of $71.5 million, up 18 percent year-over-year as revenue in each of our direct sales channels improved from the same period in 2013," said Cynosure Chairman and Chief Executive Officer Michael Davin. "North American laser revenue increased 17 percent, revenue from our Asia Pacific subsidiaries rose 46 percent, while our European direct sales channel was up 7 percent. Product and technology innovation, expanded indications and new international marketing clearances continue to drive favorable results for the Company."

    "Demand for our flagship PicoSure® Picosecond Laser Workstation continues to exceed our expectations," Davin continued. "Based on enthusiastic customer feedback and patient and physician satisfaction, we believe this technology is becoming the gold standard for the removal of tattoos and benign pigmented lesions. New FDA marketing clearances, combined with recent international regulatory approvals in Korea, Taiwan and Australia, demonstrate the successful execution of our strategy to drive growth for PicoSure worldwide."

  • Reply to

    Thomas M. Laughren

    by spook2b Oct 15, 2014 7:37 AM
    bullseyecatnip bullseyecatnip Oct 15, 2014 10:55 AM Flag

    How can some large pharma not be considering kicking the tire and vetting little/growing AVNR if only for #$%$ and giggles? ; - )

  • Reply to

    Thomas M. Laughren

    by spook2b Oct 15, 2014 7:37 AM
    bullseyecatnip bullseyecatnip Oct 15, 2014 10:50 AM Flag

    Please don't answer... how is this not some if the BEST ever and most promising news for AVNR from a highly respected Dr. Laughren who has decades of experience within in and outside of the FDA?!?
    Any advisory committee would likely look favorably... special consideration possible... breakthrough designation not unreasonable. As risky as any small bio-pharma company, AVNR no exception, shareholders have more facts and hope to look forward to than ever before, IMO.

0.050.00(0.00%)Dec 26 4:00 PMEST

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.